Mankind Pharma Strengthens Portfolio with ₹797 Crore BSV Women’s Health Acquisition

Mankind Pharma has executed a Business Transfer Agreement (BTA) with its wholly owned subsidiary, Bharat Serums and Vaccines Limited (BSV), to acquire BSV’s Branded Generic Business focused on the Women Health Rx Portfolio. The acquisition, structured as a slump sale on a going concern basis, is valued at ₹797 crore, subject to closing adjustments.

Transaction Terms and Payment Schedule

Under the terms of the agreement, 50% of the sale consideration will be paid on the Closing Date, while the remaining 50% will be settled within 150 days from the Closing Date. 

The completion of the acquisition is contingent upon preconditions, closing actions, and other terms and conditions outlined in the agreement. Mankind Pharma had provided detailed disclosures regarding this transaction in an earlier filing dated July 31, 2025.

First Quarter Financial Overview

In its first-quarter results, Mankind Pharma reported a net profit of ₹444.6 crore for Q1FY26, an 18.1% decline from ₹543 crore in the same period last year. Revenue from operations increased 24.5% to ₹3,570 crore, up from ₹2,868 crore year-on-year. 

At the operating level, EBITDA rose 26% to ₹847.6 crore, with EBITDA margin improving slightly to 23.7% from 23.4%. Diluted earnings per share (EPS) fell 20.1% to ₹10.6 for the quarter.

Domestic revenue grew 18.9% to ₹3,101 crore, while export revenue surged 81.1% to ₹469 crore, supported by the consolidation of BSV and growth in Mankind Pharma’s base business. The company’s market share increased from 4.8% in March 2025 to 4.9% in June 2025. Secondary sales for Q1FY26 rose 9.2%, outpacing the Indian pharmaceutical market’s 8.6% growth.

Mankind Pharma Share Price Update

On the BSE, Mankind Pharma Share Price closed at ₹2,464.00, down ₹15.40 or 0.62% on October 10, 2025. The stock traded within a day’s range of ₹2,454.35 to ₹2,500.00, opening at ₹2,489.05. 

The 52-week price range stands between ₹2,115.50 and ₹3,050.00, with a market capitalisation of ₹1,02,347 crore. The trading volume for the day reached 6,818 shares, indicating steady investor interest.

Read more:India’s Pharma Exports to Cross $30 Billion; Domestic Market to Double by 2030

Conclusion

The acquisition of BSV’s Women Health Portfolio strengthens Mankind Pharma’s product offerings and supports its growth strategy in the domestic pharmaceutical market. By consolidating its subsidiary’s operations, the company is positioned to expand its market presence and enhance its overall portfolio.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.